![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » GENENTECH GETS APPROVAL FOR AVASTIN TO TREAT LUNG CANCER -- UPDATE
GENENTECH GETS APPROVAL FOR AVASTIN TO TREAT LUNG CANCER -- UPDATE
Wednesday, Genentech, Inc., revealed U.S. Food and Drug Administration approval for its Avastin (bevacizumab) indicated as a first line treatment for patients with inoperable, recurrent or metastatic non-squamous, non-small cell lung cancer. The FDA approved Avastin in combination with carboplatin and paclitaxel chemotherapy, based on results from a Phase III study. Trading Markets (http://www.tradingmarkets.com/.site/news/BREAKING%20NEWS/453426/)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct